Tag: Andrew Percy

The below Parliamentary question was asked by Andrew Percy on 2016-01-14.

To ask the Secretary of State for Energy and Climate Change, how many defibrillators are provided in each building her Department manages.

Andrea Leadsom

The number of defibrillators held in buildings managed by the Department is as follows:

Building	No. of defibrillators
3 Whitehall Place, London, SW1A 2AW	1
55 Whitehall, London, SW1A 2EW	1
Atholl House, 86-88 Guild Street, Aberdeen, AB11 6AR	1

The below Parliamentary question was asked by Andrew Percy on 2016-02-09.

To ask the Secretary of State for Justice, what steps he is taking to give greater support to people with mental health vulnerabilities who come into contact with the criminal justice system.

Andrew Selous

Liaison and Diversion services place clinical staff at police stations and courts to assess and identify offenders for a range of health problems, including mental health, and then make referrals to treatment and support services. Information about their health needs can be shared so that court proceedings, decisions and sentences can be tailored to meet needs. Where appropriate offenders can be diverted towards appropriate interventions.

In April 2014, services were launched in 10 trial areas, and extended in April 2015 to a further 15 areas. This brings current coverage to over half of England. We are also exploring how problem-solving courts can support people with complex needs. A working group has been established in partnership with the judiciary which will make recommendations in due course.

The below Parliamentary question was asked by Andrew Percy on 2016-02-24.

To ask the Secretary of State for Health, what representations he has received on the proposals contained in the report, Surrogacy in the UK: Myth Busting and Reform, published in November 2015.

Jane Ellison

A search of the Department’s central correspondence system shows that the Department received 22 representations that made direct or indirect reference to the report `Surrogacy in the UK: Myth Busting and Reform’ since it was published in November 2015.

The Government has no current plans to change the legislation in respect of surrogacy arrangements.

The below Parliamentary question was asked by Andrew Percy on 2016-03-07.

To ask the Secretary of State for Communities and Local Government, what steps he is taking to ensure that there are safeguards against flooding for the construction of new houses in potential flood-risk areas.

Brandon Lewis

There are strict tests in the National Planning Policy Framework to protect people and property from flooding which all local planning authorities are expected to follow, underpinned by our planning practice guidance. The Framework is clear that local planning authorities should avoid inappropriate development in areas at risk of flooding by directing development away from areas at highest risk. Where development is necessary in a flood risk area, it must be demonstrated that it will be safe, without increasing flood risk elsewhere, and be appropriately flood resilient and resistant. Mitigation measures, such as land raising, raised building thresholds and improved flood management infrastructure, to make development acceptable in flood risk areas can be made a requirement of any planning consent.

We are clear that where the strict tests on flood risk set out in national planning policy are not met, new development should not be allowed.

The below Parliamentary question was asked by Andrew Percy on 2016-03-24.

To ask the Secretary of State for Health, how much the NHS spent on treating people with inflammatory bowel disease in (a) the last 12 months and (b) each of the last five financial years.

Jane Ellison

The information is not available in the format requested.

Such information as is available on the cost to the National Health Service of treating inflammatory bowel disease is from reference costs, which are the average unit cost to NHS hospital trusts of providing defined services to patients in a given financial year. Reference costs for acute care are collected by Healthcare Resource Group (HRG), a secondary classification system which groups similar treatments that use similar resources. Reference costs are published annually, most recently for 2014-15.

The following table reflects the costs of treating patients who are admitted to hospital and does not include the treatment of inflammatory bowel disease in outpatient or other settings outside of hospital. The costs are not comparable between years because of changes to the HRG design and to the underlying primary classification system for diseases.

Estimated total costs (£millions) to NHS hospitals of treating inflammatory bowel disease, 2010-11 to 2014-15

	2010-11	2011-12	2012-13	2013-14	2014-15
Inflammatory bowel disease	207.3	147.1	73.0	78.8	82.9
Paediatric inflammatory bowel disease	12.1	8.4	9.7	10.6	10.9
Total	219.4	155.5	82.6	89.5	93.8

Source: Reference costs, Department of Health

Notes:

1. For each HRG or other currency in the reference cost collection, NHS hospital trusts submit a unit cost and amount of activity undertaken.
2. Costs are not comparable between years:
   1. changes to the HRG design in 2011-12 resulted in the removal of HRGs specific to procedures for inflammatory bowel disease. These costs are included in other HRGs and are no longer separately identifiable.
   2. revised clinical coding guidance introduced in 2012-13 with the International Classification of Diseases 10th revision (ICD-10), fourth edition, resulted in the transfer of significant activity (and therefore costs) associated with infectious gastroenteritis and colitis to other HRGs.
3. The following HRGs are included in the table:

2010-11

FZ37F Inflammatory Bowel Disease with length of stay 1 day or less

FZ37G Inflammatory Bowel Disease with length of stay 2 days or more with Major Complications and Comorbidities (CC) with Interventions

FZ37H Inflammatory Bowel Disease with length of stay 2 days or more with Major CC without Interventions

FZ37I Inflammatory Bowel Disease with length of stay 2 days or more without Major CC with Interventions

FZ37J Inflammatory Bowel Disease with length of stay 2 days or more without Major CC without Interventions

FZ14Z Complex Procedures for Inflammatory Bowel Disease

FZ15Z Major Procedures for Inflammatory Bowel Disease

FZ28A Endoscopic or Intermediate Procedures for Inflammatory Bowel Disease 19 years and over with CC

FZ28B Endoscopic or Intermediate Procedures for Inflammatory Bowel Disease 19 years and over without CC

FZ28C Endoscopic or Intermediate Procedures for Inflammatory Bowel Disease 18 years and under

PA27Z Inflammatory Bowel Disease

2011-12

FZ37F Inflammatory Bowel Disease with length of stay 1 day or less

FZ37G Inflammatory Bowel Disease with length of stay 2 days or more with Major CC with Interventions

FZ37H Inflammatory Bowel Disease with length of stay 2 days or more with Major CC without Interventions

FZ37I Inflammatory Bowel Disease with length of stay 2 days or more without Major CC with Interventions

FZ37J Inflammatory Bowel Disease with length of stay 2 days or more without Major CC without Interventions

PA27Z Inflammatory Bowel Disease

2012-13

FZ37K Inflammatory Bowel Disease with Multiple Interventions, with CC Score 3+

FZ37L Inflammatory Bowel Disease with Multiple Interventions, with CC Score 0-2

FZ37M Inflammatory Bowel Disease with Single Intervention, with CC Score 4+

FZ37N Inflammatory Bowel Disease with Single Intervention, with CC Score 0-3

FZ37P Inflammatory Bowel Disease without Interventions, with CC Score 5+

FZ37Q Inflammatory Bowel Disease without Interventions, with CC Score 3-4

FZ37R Inflammatory Bowel Disease without Interventions, with CC Score 1-2

FZ37S Inflammatory Bowel Disease without Interventions, with CC Score 0

PA27Z Inflammatory Bowel Disease

2013-14 and 2014-15

FZ37K Inflammatory Bowel Disease with Multiple Interventions, with CC Score 3+

FZ37L Inflammatory Bowel Disease with Multiple Interventions, with CC Score 0-2

FZ37M Inflammatory Bowel Disease with Single Intervention, with CC Score 4+

FZ37N Inflammatory Bowel Disease with Single Intervention, with CC Score 0-3

FZ37P Inflammatory Bowel Disease without Interventions, with CC Score 5+

FZ37Q Inflammatory Bowel Disease without Interventions, with CC Score 3-4

FZ37R Inflammatory Bowel Disease without Interventions, with CC Score 1-2

FZ37S Inflammatory Bowel Disease without Interventions, with CC Score 0

PF27A Paediatric Inflammatory Bowel Disease with CC Score 1+

PF27B Paediatric Inflammatory Bowel Disease with CC Score 0

The below Parliamentary question was asked by Andrew Percy on 2016-04-25.

To ask the Secretary of State for Communities and Local Government, what assessment he has made of how much local authorities will be able to collect through business rates under the Government’s devolution proposals in (a) East Yorkshire, (b) North Lincolnshire and (c) elsewhere.

Mr Marcus Jones

The Government intends to move to 100% business rates retention in England by the end of this Parliament. We have confirmed that as part of the new system there will continue to be redistribution of local tax revenue between authorities and protections in place for authorities that see their business rates income fall significantly. Over the coming months we will be working with local government on the details of the scheme.

Ahead of final decisions, it is too early to assess what the impact will be on individual areas or authorities. However, based on their own estimates, East Riding of Yorkshire Council and North Lincolnshire Council expect to collect £106.9 million and £89.2 million in business rates respectively in 2016-17.

The below Parliamentary question was asked by Andrew Percy on 2016-05-23.

To ask the Secretary of State for Health, with reference to the report of Surrogacy UK, Surrogacy in the UK: Myth busting and reform, published on 28 April 2016, if he will take steps to publish a legal pathway document for intended parents and surrogates.

Jane Ellison

Surrogacy is a complex issue, the legislation about which has not been significantly addressed by respective administrations since the Surrogacy Arrangements Act was introduced in 1985. The Government recognises the arguments for the need for a review, and we have therefore asked the Law Commission, as part of the consultation on its 13th work programme this summer, to consider including a project on surrogacy.

The Department has not issued guidance about surrogacy to professional groups or the Children and Family Court Advisory and Support Service (CAFCASS). The Government recognises surrogacy as an important option for some people wishing to start a family and is currently considering how best to clarify the current legal arrangements for intended parents, surrogates and their families. The CAFCASS campaign to increase awareness of Parental Orders is ongoing and targeted at health workers, local authority registration staff and surrogacy agencies. It will be evaluated in full upon completion in autumn 2016; in-campaign monitoring indicates its messaging is reaching the target audience.

The below Parliamentary question was asked by Andrew Percy on 2015-10-26.

To ask the Secretary of State for Education, how many schools in England have (a) staff trained in CPR or (b) a defibrillator on site; and what plans her Department has to ensure that all schools have (i) such staff and (ii) on-site defibrillators.

Edward Timpson

The Department does not hold information on the number of schools which have staff trained in CPR. All schools should have at least one first-aider, and the number of first-aid personnel will be based on local circumstances, considered as part of a first aid needs assessment in the school. Recognised certificated courses ‘First Aid at Work’ or ‘Emergency First Aid at Work’ train staff in the administration of CPR.

The guidance published by the Department in November 2014 promoted a scheme to enable schools to purchase defibrillators at reduced cost. As of 23 October 2015, 735 defibrillators had been purchased by schools through this scheme. The Department does not hold information on the total number of schools with a defibrillator.

The below Parliamentary question was asked by Andrew Percy on 2015-10-26.

To ask the Secretary of State for the Home Department, what assessment she has made of the success of her Department’s policies in supporting the UK Border Force to tackle illegal immigration into the UK.

James Brokenshire

Ensuring the security of the UK’s borders and tackling illegal immigration is a priority for the Government. We keep all policies under review to ensure effectiveness.

The new Immigration Bill contains measures designed to reform the UK’s immigration system, to prevent abuse and the flouting of the law by people who should not be here. The Bill will help secure the border, support working people, clamp down on illegal immigration and protect our public services, and tackle the exploitation of low-skilled workers and increase sanctions for those involved in such practices.

The below Parliamentary question was asked by Andrew Percy on 2015-10-26.

To ask the Secretary of State for Health, what estimate his Department has made of the number of people with both ulcerative colitis and Crohn’s disease who have benefitted from the use of vedolizumab as a treatment option since February 2015; and what the cost of this treatment has been in that period.

George Freeman

Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.

Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.

In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.

In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.

NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance Crohn’s Disease Management in Adults, Children and Young People in October 2012, and Ulcerative Colitis Management in Adults, Children and Young People , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.